Deborah Doroshow

Associate Program Director for Research and Career Development · Icahn School of Medicine at Mount Sinai

Credentials: · · · · · ·

History

Medical Oncology
2018–2020
Internal Medicine
Yale Univ Sch of Med
2015–2018
Yale University, History
Yale Univ Sch of Med
2011–2015
Yale University School of Medicine in 2015 and her fellowship in hematology
2014–2015
Harvard College, History and Science
2000–2004

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet · 2020 · 1,345 citations
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Review · Nature Reviews Clinical Oncology · 2021 · First of 10 authors · 1,282 citations
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
Review · Clinical Cancer Research · 2019 · First of 9 authors · 549 citations

The Tisch Cancer Institute - Cancer Center Support Grant
National Cancer Institute · P30
Contact PI · $60K · Icahn School of Medicine at Mount Sinai
2015–2025

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
Principal investigator · Recruiting · Phase 1
Deborah Doroshow
2023–2028
Pembrolizumab for Advanced NSCLC and PS 2-3
Principal investigator · Recruiting · Phase 2
Icahn School of Medicine at Mount Sinai
2023–2027
A Study of TAVO412 in Patients with Cancer
Principal investigator · Active not recruiting · Phase 1
Tavotek Biotherapeutics
2023–2026
Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors
Principal investigator · Completed · Phase 1
Icahn School of Medicine at Mount Sinai
2022–2024